Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease.
Nerve growth factor (NGF) is important for the survival and maintenance of central cholinergic neurons, a signalling system impaired in Alzheimer's disease. We have treated 3 patients with Alzheimer's disease with a total of 6.6 mg NGF administered continuously into the lateral cerebral ventricle for 3 months in the first 2 patients and a total of 0.55 mg for 3 shorter periods in the third patient. The patients were extensively evaluated with clinical, neuropsychological, neurophysiological and neuroradiological techniques. Three months after the NGF treatment ended, a significant increase in nicotine binding was found in several brain areas in the first 2 patients and in the hippocampus in the third patient as studied by positron emission tomography. A clear cognitive amelioration could not be demonstrated, although a few neuropsychology tests showed slight improvements. The amount of slow-wave cortical activity as studied by electroencephalography was reduced in the first 2 patients. Two negative side effects occurred with NGF treatment: first, a dull, constant back pain was observed in all 3 patients, which in 1 patient was aggravated by axial loading resulting in sharp, shooting pain of short duration. When stopping the NGF infusion, the pain disappeared within a couple of days. Reducing the dose of NGF lessened the pain. Secondly, a marked weight reduction during the infusion with a clear weight gain after ending the infusion was seen in the first 2 patients. We conclude from this limited trial that, while long-term intracerebroventricular NGF administration may cause certain potentially beneficial effects, the intraventricular route of administration is also associated with negative side effects that appear to outweigh the positive effects of the present protocol. Alternative routes of administration, and/or lower doses of NGF, perhaps combined with low doses of other neurotrophic factors, may shift this balance in favor of positive effects.
Eriksdotter Jönhagen
M
M
Department of Clinical Neuroscience and Family Medicine, Division of Geriatric Medicine, Karolinska Institute, Huddinge University Hospital, Huddinge, Stockholm, Sweden.
Nordberg
A
A
Amberla
K
K
Bäckman
L
L
Ebendal
T
T
Meyerson
B
B
Olson
L
L
Seiger
Shigeta
M
M
Theodorsson
E
E
Viitanen
M
M
Winblad
B
B
Wahlund
L O
LO
D000368:Aged; D000513:Alpha Rhythm / Q000187:drug effects; D000544:Alzheimer Disease / Q000000981:diagnostic imaging / Q000188:drug therapy*; D001921:Brain / Q000098:blood supply / Q000378:metabolism; D002250:Carbon Radioisotopes; D002560:Cerebrovascular Circulation; D003072:Cognition Disorders / Q000188:drug therapy; D005260:Female; D005947:Glucose / Q000378:metabolism; D006801:Humans; D007276:Injections, Intraventricular; D008297:Male; D008875:Middle Aged; D009414:Nerve Growth Factors / Q000008:administration & dosage* / Q000009:adverse effects; D009483:Neuropsychological Tests; D009538:Nicotine; D018722:Nicotinic Agonists; D010865:Pilot Projects; D013826:Theta Rhythm / Q000187:drug effects; D014055:Tomography, Emission-Computed; D015431:Weight Loss
D002250:Carbon Radioisotopes; D009414:Nerve Growth Factors; D018722:Nicotinic Agonists; D009538:Nicotine; D005947:Glucose